Modified whole cell, cell extract and omv-based vaccines
Live vaccines, live-attenuated vaccines, dead vaccines, protein preparations for use in vaccines and OMVs for use in vaccines are free of CEACAM1-binding Opa, though max contain Opa variants that are antigenic but don't bind to CEACAM1.
1 - 43 . (canceled)
44 . A method of treatment or prevention of meningococcal disease comprising administering to a subject an effective amount of Neisseria outer membrane vesicles which contain Opa that does not bind to CEACAM1 which are substantially free of Opa that binds CEACAM1, wherein said outer membrane vesicles are from Neisseria that have been modified by mutation to express an Opa that does not bind to CEACAM1.
45 . The method of claim 44 , wherein activation or proliferation of CD4+ T cells is enhanced.
46 . The method of claim 44 , wherein said Neisseria is Neisseria meningitidis.
47 . The method of claim 44 , wherein stimulation of immune memory is improved or inhibition of T cell function is reduced.
48 . The method of claim 44 , wherein said mutation is by a method mutagenesis selected from the group consisting of transposon mutagenesis, UV light, EMS mutagenesis and NTG mutagenesis.
49 . The method of claim 44 , wherein said administering is selected from the group consisting of parenteral, intramuscular, trans-dermal, intra-nasal, oral, topical or mucosal.
50 . The method of claim 44 , wherein said outer membrane vesicles comprise a heterologous antigen.
51 . A method of treatment or prevention of meningococcal disease comprising administering to a subject an effective amount of a composition comprising Neisseria outer membrane vesicles, wherein said outer membrane vesicles are substantially free of Opa that binds to CEACAM1.
52 . The method of claim 51 , wherein stimulation of immune memory is improved or inhibition of T cell function is reduced.
53 . The method of claim 51 , wherein said composition comprises a carrier.
54 . The method of claim 53 , wherein said carrier is selected from the group consisting of saline solution, sucrose solution, or a pharmaceutically acceptable buffer solution.
55 . The method of claim 51 , wherein said composition comprises a surfactant.
56 . The method of claim 51 , wherein said composition comprises an adjuvant.
57 . The method of claim 51 , wherein said composition comprises microencapsulated outer membrane vesicles.
58 . The method of claim 57 , wherein said microencapsulated outer membrane vesicles comprise a biocompatible polymer shell or core.
59 . The method of claim 58 , wherein said biocompatible polymer shell or core is made from polylactide-co-glycolide.
59 . A method of preparing a vaccine composition for treatment or prevention of meningococcal disease, the method comprising:
(a) isolating Neisseria outer membrane vesicles which contain Opa that does not bind to CEACAM1 and which are substantially free of Opa that binds CEACAM1, wherein said outer membrane vesicles are from Neisseria that have been modified by mutation to express an Opa that does not bind to CEACAM1; and
(b) formulating the composition for use as a vaccine.
60 . A method of preparing a vaccine composition for treatment or prevention of meningococcal disease, the method comprising:
(a) obtaining a Neisseria;
(b) determining whether the Neisseria expresses an Opa protein that binds to CEACAM1;
(c) if the Neisseria expresses an Opa protein that binds to CEACAM1, discarding the Neisseria and repeating steps (a) to (c);
(d) retaining the Neisseria if it expresses a mutant or variant or fragment or derivative of Opa, wherein the mutant or variant or fragment or derivative does not bind to CEACAM1; and
(e) preparing a composition comprising the retained Neisseria of step (d).
61 . The method of claim 60 , wherein said mutant or variant or fragment or derivative is obtained by:
(i) obtaining a Neisseria;
(ii) carrying out mutagenesis on the Neisseria;
(iii) determining whether the Neisseria expresses a mutant or fragment or variant or derivative of an Opa protein that does not bind to CEACAM1;
(iv) isolating said mutant or variant or fragment or derivative, wherein the mutant or variant or fragment or derivative does not bind to CEACAM1.
62 . The method of claim 61 , wherein said mutagenesis is selected from the group consisting of transposon mutagenesis, UV light, EMS mutagenesis and NTG mutagenesis.
63 . The method of claim 60 , wherein said determining comprises exposing said Opa protein to a CEACAM1-Fc fusion protein in an ELISA assay.
64 . The method of claim 63 , wherein said determining further comprises contacting said Opa protein with an Opa-specific monoclonal antibody.
65 . The method of claim 60 , wherein said determining comprises characterizing the interaction between said Opa protein and CEACAM1 by ELISA.
66 . The method of claim 61 , further comprising:
(v) raising an antibody to the mutant or fragment or variant or derivative; and
(vi) determining whether the antibody also binds to an Opa protein that binds to CEACAM1.
67 . The method of claim 60 , wherein the Neisseria is Neisseria meningitidis.
68 . The method of claim 60 , comprising preparing an outer membrane vesicle from the retained Neisseria.